| Autor: |
Herrala M; Research Group of Oral Health Sciences, Faculty of Medicine, Oulu University Hospital, University of Oulu, 90220 Oulu, Finland.; Institute of Dentistry, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.; Medical Research Center Oulu, Oulu University Hospital, University of Oulu, 90014 Oulu, Finland., Turunen S; School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland., Hanhineva K; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.; Department of Life Technologies, Food Chemistry and Food Development Unit, University of Turku, 20014 Turku, Finland., Lehtonen M; School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland., Mikkonen JJW; Institute of Dentistry, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.; Department of Applied Physics, University of Eastern Finland, 70211 Kuopio, Finland., Seitsalo H; Private Dental Clinic Hammas&Hammas, 00130 Helsinki, Finland., Lappalainen R; Department of Applied Physics, University of Eastern Finland, 70211 Kuopio, Finland., Tjäderhane L; Medical Research Center Oulu, Oulu University Hospital, University of Oulu, 90014 Oulu, Finland.; Department of Oral and Maxillofacial Diseases, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland., Niemelä RK; Department of Rheumatology, Oulu University Hospital, 90220 Oulu, Finland., Salo T; Department of Oral and Maxillofacial Diseases, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.; Translational Immunology Research Program (TRIMM), University of Helsinki, 00014 Helsinki, Finland.; Department of Pathology, Faculty of Medicine, University of Helsinki, Helsinki University Hospital, 00014 Helsinki, Finland.; Cancer and Translational Medicine Research Unit, University of Oulu, 90014 Oulu, Finland., Myllymaa S; Department of Applied Physics, University of Eastern Finland, 70211 Kuopio, Finland.; Diagnostic Imaging Center, Kuopio University Hospital, 70029 Kuopio, Finland., Kullaa AM; Research Group of Oral Health Sciences, Faculty of Medicine, Oulu University Hospital, University of Oulu, 90220 Oulu, Finland.; Institute of Dentistry, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.; Educational Dental Clinic, Kuopio University Hospital, 90220 Kuopio, Finland., Kärkkäinen O; School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland. |
| Abstrakt: |
Saliva is a complex oral fluid, and plays a major role in oral health. Primary Sjögren's syndrome (pSS), as an autoimmune disease that typically causes hyposalivation. In the present study, salivary metabolites were studied from stimulated saliva samples ( n = 15) of female patients with pSS in a group treated with low-dose doxycycline (LDD), saliva samples ( n = 10) of non-treated female patients with pSS, and saliva samples ( n = 14) of healthy age-matched females as controls. Saliva samples were analyzed with liquid chromatography mass spectrometry (LC-MS) based on the non-targeted metabolomics method. The saliva metabolite profile differed between pSS patients and the healthy control (HC). In the pSS patients, the LDD treatment normalized saliva levels of several metabolites, including tyrosine glutamine dipeptide, phenylalanine isoleucine dipeptide, valine leucine dipeptide, phenylalanine, pantothenic acid (vitamin B5), urocanic acid, and salivary lipid cholesteryl palmitic acid (CE 16:0), to levels seen in the saliva samples of the HC. In conclusion, the data showed that pSS is associated with an altered saliva metabolite profile compared to the HC and that the LLD treatment normalized levels of several metabolites associated with dysbiosis of oral microbiota in pSS patients. The role of the saliva metabolome in pSS pathology needs to be further studied to clarify if saliva metabolite levels can be used to predict or monitor the progress and treatment of pSS. |
